Macrophage Checkpoint Nanoimmunotherapy Has the Potential to Reduce Malignant Progression in Bioengineered In Vitro Models of Ovarian Cancer
ACS Applied Bio Materials · 2024
DOI: 10.1021/acsabm.4c00076 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Bio Materials, 2024. Verfasst von Sabrina N VandenHeuvel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Texas A&M University, 3120 TAMU, College Station, Texas 77843, United States. Hauptthemen laut MEDLINE: Immunotherapy, Macrophages, Nanoparticles, Ovarian Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NICHD NIH HHS, Texas A and M Engineering Experiment Station, Texas A and M University.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Texas A&M University, 3120 TAMU, College Station, Texas 77843, United States.
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, Texas 77030, United States.
- School of Engineering Medicine, Texas A&M University, 1020 Holcombe Boulevard, Houston, Texas 77030, United States.
- Division of Gynecologic Oncology, Houston Methodist Hospital, 6550 Fannin Street, Houston, Texas 77030, United States.
- Department of Obstetrics and Gynecology, Houston Methodist Hospital, 6550 Fannin Street, Houston, Texas 77030, United States.
- Houston Methodist Neal Cancer Center, 6445 Main Street, Houston, Texas 77030, United States.
ORCID-Profile: Shreya A Raghavan
Förderung
- NCI NIH HHS
- NICHD NIH HHS
- Texas A and M Engineering Experiment Station, Texas A and M University
- National Institutes of Health
- Dr. and Mrs. Kaplan Gynecologic Cancer Fund
Zitieren
APA
VandenHeuvel, S. N., Chau, E., Mohapatra, A., Dabbiru, S., Roy, S., O'Connell, C., Kamat, A., Godin, B., & Raghavan, S. A. (2024). Macrophage Checkpoint Nanoimmunotherapy Has the Potential to Reduce Malignant Progression in Bioengineered In Vitro Models of Ovarian Cancer. ACS Applied Bio Materials. https://doi.org/10.1021/acsabm.4c00076
Vancouver
VandenHeuvel SN, Chau E, Mohapatra A, Dabbiru S, Roy S, O'Connell C, et al. Macrophage Checkpoint Nanoimmunotherapy Has the Potential to Reduce Malignant Progression in Bioengineered In Vitro Models of Ovarian Cancer. ACS Applied Bio Materials. 2024. doi:10.1021/acsabm.4c00076
BibTeX
@article{VandenHeuvel2024,
author = {VandenHeuvel, Sabrina N and Chau, Eric and Mohapatra, Arpita and Dabbiru, Sameera and Roy, Sanjana and O'Connell, Cailin and Kamat, Aparna and Godin, Biana and Raghavan, Shreya A},
title = {Macrophage Checkpoint Nanoimmunotherapy Has the Potential to Reduce Malignant Progression in Bioengineered In Vitro Models of Ovarian Cancer},
journal = {ACS Applied Bio Materials},
year = {2024},
doi = {10.1021/acsabm.4c00076}
}
EUVIMED